Key statistics
On Friday, HUTCHMED (China) Ltd (HCM:LSE) closed at 278.00, -21.25% below its 52-week high of 353.00, set on May 10, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 279.00 |
---|---|
High | 281.00 |
Low | 277.00 |
Bid | 273.00 |
Offer | 300.00 |
Previous close | 281.00 |
Average volume | 38.60k |
---|---|
Shares outstanding | 871.56m |
Free float | 501.29m |
P/E (TTM) | -- |
Market cap | 23.79bn HKD |
EPS (TTM) | -0.3887 HKD |
Data delayed at least 20 minutes, as of Nov 22 2024 16:35 GMT.
More ▼
- FRUZAQLA® Launched in Japan by Takeda
- HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan
- Appointment of Independent Non-executive Director
- HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
- Clinical Data to be Presented at ASH and ESMO Asia
- HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress
- First Commercial Milestone Payment
- Total Voting Rights
- HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda
- Vesting of awards under the LTIP
More ▼
Investors Chronicle View
The last IC recommendation on HUTCHMED (China) Ltd shares was Buy at 227.00 on 31 Jul 2023Read the full article